These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33955628)

  • 1. Reduction of telogen rate and increase of hair density in androgenetic alopecia by a cosmetic product: Results of a randomized, prospective, vehicle-controlled double-blind study in men.
    Welzel J; Wolff HH; Gehring W
    J Cosmet Dermatol; 2022 Mar; 21(3):1057-1064. PubMed ID: 33955628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of an oral supplement containing amino acids, iron, selenium, and marine hydrolyzed collagen in subjects with hair loss (androgenetic alopecia, AGA or FAGA or telogen effluvium). A prospective, randomized, 3-month, controlled, assessor-blinded study.
    Milani M; Colombo F;
    Skin Res Technol; 2023 Jun; 29(6):e13381. PubMed ID: 37357646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of ALRV5XR in women with androgenetic alopecia or telogen effluvium: A randomised, double-blinded, placebo-controlled clinical trial.
    Feldman PR; Fiebig KM; Piwko C; Mints BM; Brown D; Cahan DJ; Guevara-Aguirre J
    EClinicalMedicine; 2021 Jul; 37():100978. PubMed ID: 34235415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of a new 5% minoxidil formulation in male androgenetic alopecia: A randomized, placebo-controlled, double-blind, noninferiority study.
    Blume-Peytavi U; Issiakhem Z; Gautier S; Kottner J; Wigger-Alberti W; Fischer T; Hoffmann R; Tonner F; Bouroubi A; Voisard JJ
    J Cosmet Dermatol; 2019 Feb; 18(1):215-220. PubMed ID: 29659116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.
    Olsen EA; Dunlap FE; Funicella T; Koperski JA; Swinehart JM; Tschen EH; Trancik RJ
    J Am Acad Dermatol; 2002 Sep; 47(3):377-85. PubMed ID: 12196747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, vehicle-controlled clinical study of hair regeneration using adipose-derived stem cell constituent extract in androgenetic alopecia.
    Tak YJ; Lee SY; Cho AR; Kim YS
    Stem Cells Transl Med; 2020 Aug; 9(8):839-849. PubMed ID: 32420695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new combination of molecules for the treatment of androgenetic alopecia and telogen effluvium: a double-blind randomized, monocentric, placebo-controlled study.
    Rossi A; Magri F; DI Fraia M; Caro G; Fortuna MC; Piacentini M; Celleno L
    Ital J Dermatol Venerol; 2022 Feb; 157(1):78-83. PubMed ID: 33878855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of a cosmetic phyto-caffeine shampoo in female androgenetic alopecia.
    Bussoletti C; Tolaini MV; Celleno L
    G Ital Dermatol Venereol; 2020 Aug; 155(4):492-499. PubMed ID: 29512972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of ALRV5XR in men with androgenetic alopecia: A randomised, double-blinded, placebo-controlled clinical trial.
    Feldman PR; Fiebig KM; Piwko C; Mints BM; Brown D; Cahan DJ; Guevara-Aguirre J
    EClinicalMedicine; 2021 Oct; 40():101124. PubMed ID: 34541479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies.
    Gassmueller J; Hoffmann R; Webster A
    Br J Dermatol; 2008 Jan; 158(1):109-15. PubMed ID: 17986309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss: a randomized, double-blind, comparative clinical trial.
    Shin HS; Won CH; Lee SH; Kwon OS; Kim KH; Eun HC
    Am J Clin Dermatol; 2007; 8(5):285-90. PubMed ID: 17902730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Single-Centre, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Investigate the Efficacy and Safety of Minoxidil Topical Foam in Frontotemporal and Vertex Androgenetic Alopecia in Men.
    Hillmann K; Garcia Bartels N; Kottner J; Stroux A; Canfield D; Blume-Peytavi U
    Skin Pharmacol Physiol; 2015; 28(5):236-44. PubMed ID: 25765348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Minoxidil Combined With Photobiomodulation for the Treatment of Male Androgenetic Alopecia. A Double-Blind Half-Head Controlled Trial.
    Ferrara F; Kakizaki P; de Brito FF; Contin LA; Machado CJ; Donati A
    Lasers Surg Med; 2021 Nov; 53(9):1201-1207. PubMed ID: 33998004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.
    Olsen EA; Whiting D; Bergfeld W; Miller J; Hordinsky M; Wanser R; Zhang P; Kohut B
    J Am Acad Dermatol; 2007 Nov; 57(5):767-74. PubMed ID: 17761356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of hair loss in men with androgenetic alopecia (male pattern hair loss): long-term (5-year) controlled observational data in placebo-treated patients.
    Kaufman KD; Girman CJ; Round EM; Johnson-Levonas AO; Shah AK; Rotonda J
    Eur J Dermatol; 2008; 18(4):407-11. PubMed ID: 18573713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study of a novel treatment for androgenetic alopecia using enriched cell culture medium: clinical trials.
    Lindenbaum ES; Feitelberg AL; Tendler M; Beach D; Gamliel-Lazarovich A; Har-Shai Y; Hirshowitz B
    Dermatol Online J; 2003 Feb; 9(1):4. PubMed ID: 12639462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar response patterns to topical minoxidil foam 5% in frontal and vertex scalp of men with androgenetic alopecia: a microarray analysis.
    Mirmirani P; Consolo M; Oyetakin-White P; Baron E; Leahy P; Karnik P
    Br J Dermatol; 2015 Jun; 172(6):1555-1561. PubMed ID: 25204361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia.
    Blume-Peytavi U; Lönnfors S; Hillmann K; Garcia Bartels N
    J Am Acad Dermatol; 2012 May; 66(5):794-800. PubMed ID: 21875758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-level laser therapy for the treatment of androgenetic alopecia in Thai men and women: a 24-week, randomized, double-blind, sham device-controlled trial.
    Suchonwanit P; Chalermroj N; Khunkhet S
    Lasers Med Sci; 2019 Aug; 34(6):1107-1114. PubMed ID: 30569416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial.
    Fischer TW; Burmeister G; Schmidt HW; Elsner P
    Br J Dermatol; 2004 Feb; 150(2):341-5. PubMed ID: 14996107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.